Compare WCN & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WCN | TEVA |
|---|---|---|
| Founded | 1997 | 1901 |
| Country | Canada | Israel |
| Employees | N/A | 32842 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.0B | 41.6B |
| IPO Year | 2005 | N/A |
| Metric | WCN | TEVA |
|---|---|---|
| Price | $152.54 | $35.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $204.21 | $38.63 |
| AVG Volume (30 Days) | 1.4M | ★ 5.8M |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 74.48 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $9,466,915,000.00 | N/A |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $6.18 | $2.97 |
| P/E Ratio | $178.80 | ★ $28.19 |
| Revenue Growth | ★ 6.14 | N/A |
| 52 Week Low | $152.66 | $14.99 |
| 52 Week High | $198.00 | $37.35 |
| Indicator | WCN | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 68.24 |
| Support Level | N/A | $30.53 |
| Resistance Level | $171.39 | $37.35 |
| Average True Range (ATR) | 3.82 | 1.02 |
| MACD | -1.02 | 0.37 |
| Stochastic Oscillator | 2.18 | 81.70 |
Waste Connections is a North American waste management company focused on integrated waste collection services. The firm primarily focuses on residential, commercial, municipal, and industrial waste collection, with a secondary market focus on rural areas. With 113 landfills and 222 transfer stations as of 2024, it is the third-largest waste management company by revenue. Revenue is split among six operating segments: Western, Southern, Eastern, Central, Canada, and Midsouth.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.